TBANK: Protocol for Collecting, Banking, and Distributing Human Tissue Samples: St. Jude Children’s Research Hospital Biorepository

Description

The aims of this protocol are: to collect and store diseased and normal tissue and body fluid samples from new and returning patients at St. Jude Children's Research Hospital, affiliated sites and collaborating institutions; to collect and store samples from relatives of St. Jude patients; to collect and store retrospective and prospective pertinent corresponding clinical and laboratory data on disease characterization, treatment, and outcome; and to serve as a source of human biological samples and corresponding laboratory and clinical data.

Objectives

To provide a high quality repository of tumor and normal samples to facilitate translational research performed by St Jude Faculty and their collaborators.

Banked tissue may be used for research that leads to new tests or products that can be sold. Tissue may be used in studies by St. Jude researchers collaborating with other medical centers or commercial companies doing medical research. Some research using your samples may be funded by industry sponsors. Only the amount of tissue needed for their research will be shared with these collaborating researchers. They will be required to return any unused portion to St. Jude.

Eligibility

• Participant and sample eligibility criteria for St. Jude patients
• The institutional goal is for all St. Jude patients to be approached for TBANK enrollment.
• Eligible samples include the following:
  • Any leftover tissues procured for diagnostic purposes.
  • Tissue procured per an IRB-approved research protocol.
• Leftover material procured for diagnostic purposes (before or after patient registration at St. Jude) and obtained through procedures performed at LeBonheur Children’s Medical Center or other collaborating site.
• Tissue or body fluid samples procured for research purposes at protocol-specific collaborating institutions that have ratified this protocol by a site IRB.

Eligible samples include the following:

• Patients with solid and brain tumors
  • With no evidence of metastatic disease
    • Any peripheral blood or bone marrow sample.
    • Tissue sample grossly uninvolved by disease.
  • With metastatic disease
    • Peripheral blood or bone marrow sample after remission.
    • Tissue sample grossly uninvolved by disease.
• Patients with hematopoietic tumors, including leukemia
  • Peripheral blood or bone marrow after attainment of morphologic remission.
• Normal tissue samples obtained from patients and their relatives

Principal Investigator

Charles Mullighan, MBBS, MD